

To / Destinataire : All Retail Pharmacists and Staff	From / Expéditeur : Amanda Clair
Date : January 13, 2020	Administrative Officer - PEI Pharmacare
Subject / Objet : Revised January 2020 Update to the Maximum Reimbursable Price List	Tel / Tél : (902) 620-3288 Fax / Téléc : (902) 368-4905
	E-mail / Courriel : adclair@ihis.org

The January 2020 update to the PEI Pharmacare Maximum Reimbursable Price (MRP) List has been published. Changes for products added to the MRP list will come into effect on January 27, 2020. Changes in pricing related to the addition of new MRP categories will come into effect on the 1st February, 2020.

Adobe Acrobat (pdf) and Excel versions of the complete list can be downloaded from the Government website at: <http://healthpei.ca/pharmacare> under "Resources for Pharmacists".

All product availability and pricing has been confirmed with manufacturers prior to publication of this update.

Please contact the PEI Pharmacare Office at 368-4947 (Charlottetown) or 1-877-577-3737 (toll-free in PEI) if you are unable to access a copy of the list online.

Refer to the Formulary to determine coverage of products under specific drug programs.

In addition, some of the MRP Categories are only available through the Palliative Home Care Drug Pilot Project.

NEW MRP CATEGORIES

There are no new MRP categories to report.

PRODUCTS ADDED TO THE MRP LIST

CLINDAMYCIN 1% TOPICAL SOLUTION	02483769
DULOXETINE 30MG DELAYED RELEASE CAPSULE (SNS)	02490889
DULOXETINE 60MG DELAYED RELEASE CAPSULE (SNS)	02490897
JAMP-DORZOLAMIDE-TIMOLOL 2%-0.5% OPH SOL'N	02457539
PMS-EFAVIRENZ-EMTRICITABINE-TENOFOVIR 600MG/200MG/300MG TABLET	02487284
SANDOZ-EFAVIRENZ-EMTRICITABINE-TENOFOVIR 600MG/200MG/300MG TABLET	02484676

CHANGES TO MRP PRICES

There are no changes to MRP prices to report.

DELETED MRP CATEGORIES

OFLOXACIN	02143291	OCUFLOX	ALL
0.3% OPH SOLN	02248398	APO-OFLOXACIN (DISC JAN/19)	APX
TIMOLOL MALEATE	0755826	APO-TIMOP (DISC JAN/19)	APX
0.25% OPH SOL'N	02166712	SANDOZ TIMOLOL	SDZ

DISCONTINUED PRODUCTS

These products will not appear in the next publication of the Drug Programs Formulary, but will remain as benefits for the next twelve months.

ACT-DORZOTIMOLOL 2% & 0.5% OPH SOL'N (DISC JUN/19)	02404389
APO-HYDROMORPH CR 3MG CAPSULE	02476614
APO-HYDROMORPH CR 4.5MG CAPSULE	02476622
APO-HYDROMORPH CR 6MG CAPSULE	02476630
APO-HYDROMORPH CR 9MG CAPSULE	02476649
APO-HYDROMORPH CR 12MG CAPSULE	02476657
APO-HYDROMORPH CR 18MG CAPSULE	02476665
APO-HYDROMORPH CR 24MG CAPSULE	02476673
APO-HYDROMORPH CR 30MG CAPSULE	02476681
MINT-DORZOLAMIDE/TIMOLOL 2% & 0.5% OPH SOL'N (DISC MAY/19)	02443090

CHANGE IN MANUFACTURER

FLURBIPROFEN 100MG TABLET DIN 01912038 (previously Apo-Flurbiprophen-APX)	<u>MFR</u> AAA
---	--------------------------